Non-Invasive Prenatal Diagnosis (NIPD): UKGTN Approval of Gene Dossiers for fetal sex determination for Congenital Adrenal Hyperplasia (CAH) and X-linked Conditions (excluding haemophilia)

5 February 2010

The UKGTN Steering Group endorsed the recommendations of the gene dossiers for using Non-Invasive Prenatal Diagnosis (NIPD) to determine fetal sex for Congenital Adrenal Hyperplasia (CAH) and X-linked conditions (excluding haemophilia) in the NHS. Best practice guidelines and care pathways have been developed, in collaboration with the service providers, and highlight how NIPD can improve the equity of access and quality of care offered to woman whose pregnancy is at risk of these conditions. 

The best practice guidelines and care pathways are available for download from:

Congenital Adrenal Hyperplasia: best practice guidelines and care pathways 
X-linked conditions (excluding haemophilia): best practice guidelines and care pathways

The gene dossiers submitted by each member laboratory for fetal sex determination for  the two clinical scenarios  are available for download: